Abstract
Collectively, our study revealed that the m<sup>6</sup>A "reader" IGF2BP2 promotes lung cancer radioresistance by forming a positive feedback loop with SLC7A5, suggesting that IGF2BP2 may be a potential therapeutic target to control radioresistance in lung cancer.
Introduction: The Challenge of Radioresistance
Radiotherapy is a primary treatment modality for non-small cell lung cancer (NSCLC). However, the development of radioresistance often leads to treatment failure and tumor recurrence. While $N^6$-methyladenosine ($m^6A$) RNA modification is known to regulate cancer progression, its specific role in radioresistance has remained largely unexplored. This study identifies the $m^6A$ "reader" IGF2BP2 as a critical driver of radioresistance in lung cancer through a self-reinforcing metabolic and epigenetic feedback loop.
Methods and Data Sources
The researchers utilized a comprehensive approach to map the mechanisms of resistance:
- Bioinformatics & Clinical Data: Analysis of TCGA-LUAD datasets and tissue microarrays correlated IGF2BP2 expression with patient outcomes.
- Molecular Assays: RIP-qPCR, MeRIP-qPCR, and ChIP-qPCR were used to define the interactions between IGF2BP2, $m^6A$ sites, and gene promoters.
- Functional Radiobiology: Clonogenic survival assays and neutral comet assays quantified cellular survival and DNA damage following radiation.
- In Vivo Validation: Subcutaneous xenograft mouse models were employed to test the efficacy of targeting the IGF2BP2 pathway in combination with radiotherapy.
The IGF2BP2-SLC7A5 Feedback Loop
The study uncovered a sophisticated "vicious cycle" that sustains radioresistance:
- RNA Stabilization: IGF2BP2 binds to and stabilizes the mRNA of the amino acid transporter SLC7A5.
- Metabolic Reprogramming: Increased SLC7A5 levels lead to higher Methionine uptake.
- Epigenetic Activation: Methionine is converted to SAM, facilitating H3K4me3 histone modification at the IGF2BP2 promoter, which further increases its expression.
- Pathway Activation: This loop activates the AKT/mTOR signaling pathway, enhancing the cell's ability to repair radiation-induced DNA damage.
Key Results: Sensitizing Resistant Tumors
The researchers demonstrated that disrupting this loop significantly enhances radiation sensitivity.
- Clinical Impact: High IGF2BP2 expression is a negative prognostic factor in lung cancer patients, as shown in TCGA survival analysis (Fig. 1D).
- DNA Damage Visualization: Knocking down IGF2BP2 (shBP2#1/2) resulted in significantly increased DNA strand breaks after radiation, as evidenced by longer "comet tails" in neutral comet assays.
- In Vivo Efficacy: In mouse models, silencing IGF2BP2 combined with radiation (IR) led to a dramatic reduction in tumor volume and mass compared to radiation alone (Fig. 1L).
- Regulatory Control: The study identified the FBW7/GSK3β axis as a natural regulator that degrades IGF2BP2, providing a blueprint for potential therapeutic intervention.
Conclusion and Future Directions
This research highlights IGF2BP2 as a pivotal regulator of radioresistance and a promising therapeutic target. While the mechanism is well-defined, future work is needed to develop clinical-grade inhibitors or PROTACs that can effectively target IGF2BP2. Understanding the full spectrum of ubiquitin ligases involved in this pathway will also be crucial for optimizing treatment strategies to overcome resistance in NSCLC patients.
Summary updated